Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Titre
Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field
Sujet
Description
Two phase 2 randomised clinical trials evaluating ChAd3-EBO-Z administered to healthy adults in Cameroon, Mali, Nigeria, and Senegal and healthy children in Mali and Senegal are reported by Milagritos Tapia and colleagues in The Lancet Infectious Diseases. No vaccine-related serious adverse events were observed and adverse events were minimal.
Date
2020-03-19
Type
Citer ce document
Bavari, Sina, and Patrick L. Iversen. 2020. "Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field." The Lancet Infectious Diseases.
Accessibilité
Through subscription on Lancet.
Was this resource helpful?